CY1119145T1 - Μεθοδοι για αγωγη ανοσιακων διαταραχων που συσχετιζονται με μεταμοσχευση μοσχευματων με ευδιαλυτα μορια μεταλλαγματων toy ctla4 - Google Patents

Μεθοδοι για αγωγη ανοσιακων διαταραχων που συσχετιζονται με μεταμοσχευση μοσχευματων με ευδιαλυτα μορια μεταλλαγματων toy ctla4

Info

Publication number
CY1119145T1
CY1119145T1 CY20171100812T CY171100812T CY1119145T1 CY 1119145 T1 CY1119145 T1 CY 1119145T1 CY 20171100812 T CY20171100812 T CY 20171100812T CY 171100812 T CY171100812 T CY 171100812T CY 1119145 T1 CY1119145 T1 CY 1119145T1
Authority
CY
Cyprus
Prior art keywords
treatment
ctla4
soluble
toi
translators
Prior art date
Application number
CY20171100812T
Other languages
English (en)
Inventor
David Hagerty
James Rusnak
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1119145T1 publication Critical patent/CY1119145T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Transplantation (AREA)
  • Medical Informatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει χρήση ευδιάλυτων μορίων μεταλλαγμάτων του CTLA4 τα οποία δεσμεύονται με μεγαλύτερη ακορεστότητα («απληστία») με το αντιγόνο CD80 και/ή CD86 από ότι το CTLA4 φυσικού-τύπου ή το μη-μεταλλαγμένο CTLA4lg στην αγωγή ανοσιακών διαταραχών που συσχετίζονται με μεταμόσχευση μοσχευμάτων.
CY20171100812T 2005-04-06 2017-07-28 Μεθοδοι για αγωγη ανοσιακων διαταραχων που συσχετιζονται με μεταμοσχευση μοσχευματων με ευδιαλυτα μορια μεταλλαγματων toy ctla4 CY1119145T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66877405P 2005-04-06 2005-04-06
PCT/US2006/012648 WO2006108035A1 (en) 2005-04-06 2006-04-05 Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules

Publications (1)

Publication Number Publication Date
CY1119145T1 true CY1119145T1 (el) 2018-02-14

Family

ID=36694299

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100812T CY1119145T1 (el) 2005-04-06 2017-07-28 Μεθοδοι για αγωγη ανοσιακων διαταραχων που συσχετιζονται με μεταμοσχευση μοσχευματων με ευδιαλυτα μορια μεταλλαγματων toy ctla4

Country Status (25)

Country Link
US (2) US7482327B2 (el)
EP (1) EP1868635B1 (el)
JP (1) JP2008535841A (el)
KR (1) KR101235484B1 (el)
CN (1) CN101198347A (el)
AR (1) AR055052A1 (el)
AU (1) AU2006231622B2 (el)
BR (1) BRPI0608144A2 (el)
CA (1) CA2603970A1 (el)
CY (1) CY1119145T1 (el)
DK (1) DK1868635T3 (el)
EA (1) EA013122B1 (el)
ES (1) ES2634260T3 (el)
HR (1) HRP20171121T8 (el)
IL (1) IL186189A (el)
LT (1) LT1868635T (el)
ME (1) ME02930B (el)
MX (1) MX2007012222A (el)
NO (1) NO342966B1 (el)
NZ (2) NZ561655A (el)
PL (1) PL1868635T3 (el)
PT (1) PT1868635T (el)
RS (1) RS56138B1 (el)
SI (1) SI1868635T1 (el)
WO (1) WO2006108035A1 (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
SI1868635T1 (sl) * 2005-04-06 2017-07-31 Bristol-Myers Squibb Company Postopki za zdravljenje imunskih motenj, povezanih s transplantacijo presadkov s topnimi mutiranimi CTLA4 molekulami
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
US7528111B2 (en) * 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
WO2008014035A2 (en) * 2006-07-25 2008-01-31 The Regents Of The University Of California Modulation of nkg2d and method for treating or preventing solid organ allograft rejection
ES2399088T3 (es) 2007-11-01 2013-03-25 Perseid Therapeutics Llc Polipéptidos y ácidos nucleicos inmunosupresores
US20110223188A1 (en) * 2008-08-25 2011-09-15 Solomon Langermann Targeted costimulatory polypeptides and methods of use to treat cancer
WO2010049935A1 (en) * 2008-10-30 2010-05-06 Yeda Research And Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
US20100297123A1 (en) * 2009-05-15 2010-11-25 Garrison Fathman C Combination therapy to inhibit t cell effector function
TW201134481A (en) 2010-03-12 2011-10-16 Abbott Biotherapeutics Corp CTLA4 proteins and their uses
ES2589678T3 (es) 2010-09-08 2016-11-15 Yeda Research And Development Co. Ltd. Uso de linfocitos T de memoria central anti-terceros para el tratamiento anti-leucemia/linfoma
US20130183322A1 (en) 2010-09-08 2013-07-18 Yeda Research And Development Co., Ltd. Immunosuppressive drug combination for a stable and long term engraftment
SG11201400513PA (en) 2011-09-08 2014-06-27 Yeda Res & Dev Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
SG10201610288TA (en) 2011-10-13 2017-02-27 Bristol Myers Squibb Co Antibody polypeptides that antagonize cd40l
JP2016515706A (ja) 2013-03-28 2016-05-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 共刺激遮断抵抗性拒絶のリスクがある患者を同定するための方法
CN104673822A (zh) * 2013-11-27 2015-06-03 深圳先进技术研究院 一种重组载体及其制备方法和应用
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
US20170051059A1 (en) 2014-03-19 2017-02-23 Bristol-Myers Squibb Company Methods of treating transplant rejection using a domain antibody directed against cd40
WO2016168771A2 (en) 2015-04-17 2016-10-20 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
CA2991690A1 (en) 2015-07-16 2017-01-19 Yeda Research And Development Co. Ltd. Genetically modified anti-third party central memory t cells and use of same in immunotherapy
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
US11555178B2 (en) 2017-01-18 2023-01-17 Yeda Research And Development Co. Ltd. Genetically modified veto cells and use of same in immunotherapy
US10286036B2 (en) 2017-05-12 2019-05-14 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
KR20230020022A (ko) 2017-10-10 2023-02-09 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
US11925640B2 (en) 2018-06-22 2024-03-12 Mayo Foundation For Medical Education And Research Methods and materials for improving arteriovenous fistula maturation and maintaining arteriovenous fistula functionality
EP3818147A4 (en) * 2018-07-06 2021-11-24 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS TO IMPROVE TRANSPLANT SUCCESS
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
CN115089718B (zh) * 2021-11-30 2024-05-28 杭州瑞普晨创科技有限公司 用于异种移植的免疫抑制剂组合和免疫抑制方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
AU661854B2 (en) 1991-06-27 1995-08-10 Bristol-Myers Squibb Company CTL4A receptor, fusion proteins containing it and uses thereof
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
CA2436139A1 (en) * 2001-01-26 2002-08-01 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
ES2302811T3 (es) * 2001-05-23 2008-08-01 Bristol-Myers Squibb Company Procedimiento para proteger transplantes de islotes alogenicos usando moleculas mutantes soblules ctla4.
AU2003243152A1 (en) * 2002-04-19 2003-11-03 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
CN101857851A (zh) 2002-12-23 2010-10-13 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法
BR0316882A (pt) 2002-12-23 2005-10-25 Bristol Myers Squibb Co Melhora na qualidade de produtos em processos de cultura de células de mamìferos para a produção de proteìnas
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
SI1868635T1 (sl) * 2005-04-06 2017-07-31 Bristol-Myers Squibb Company Postopki za zdravljenje imunskih motenj, povezanih s transplantacijo presadkov s topnimi mutiranimi CTLA4 molekulami

Also Published As

Publication number Publication date
EP1868635B1 (en) 2017-05-17
DK1868635T3 (en) 2017-09-11
ES2634260T3 (es) 2017-09-27
IL186189A0 (en) 2008-01-20
JP2008535841A (ja) 2008-09-04
US20100041602A1 (en) 2010-02-18
AR055052A1 (es) 2007-08-01
LT1868635T (lt) 2017-07-10
HRP20171121T1 (hr) 2017-10-06
US7482327B2 (en) 2009-01-27
CN101198347A (zh) 2008-06-11
RS56138B1 (sr) 2017-10-31
HRP20171121T8 (hr) 2017-11-03
NO342966B1 (no) 2018-09-10
KR101235484B1 (ko) 2013-02-22
PT1868635T (pt) 2017-07-27
KR20070119728A (ko) 2007-12-20
BRPI0608144A2 (pt) 2009-11-17
EP1868635A1 (en) 2007-12-26
AU2006231622B2 (en) 2012-07-05
ME02930B (me) 2018-04-20
MX2007012222A (es) 2007-12-06
CA2603970A1 (en) 2006-10-12
NO20075078L (no) 2008-01-04
NZ576434A (en) 2010-06-25
SI1868635T1 (sl) 2017-07-31
WO2006108035A1 (en) 2006-10-12
EA013122B1 (ru) 2010-02-26
US20070009511A1 (en) 2007-01-11
IL186189A (en) 2015-11-30
AU2006231622A1 (en) 2006-10-12
NZ561655A (en) 2010-01-29
PL1868635T3 (pl) 2017-10-31
EA200702180A1 (ru) 2008-10-30

Similar Documents

Publication Publication Date Title
CY1119145T1 (el) Μεθοδοι για αγωγη ανοσιακων διαταραχων που συσχετιζονται με μεταμοσχευση μοσχευματων με ευδιαλυτα μορια μεταλλαγματων toy ctla4
CY1118691T1 (el) Συνθεσεις και μεθοδοι χρησης για αντισωματα κατα σκληροστινης
BRPI0413466A (pt) anticorpos igf-1r humanos modificados
CY1121789T1 (el) Νεες ανοσοενισχυτικες συνθεσεις
CY1123526T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων ογκων των νευρωνων και του εγκεφαλου
ATE494303T1 (de) An humane leukozytenantigen-(hla-)klasse-i- oder ii-moleküle bindende tumorassoziierte peptide und damit im zusammenhang stehender impfstoff gegen krebs
CY1117454T1 (el) Μεθοδοι και μεσα για την αποτελεσματικη παραλειψη του εξονιου 45 εις το προ-mrna της μυϊκης δυστροφιας τυπου duchenne
EP4276198A3 (en) Nucleic acid synthesis and sequencing using tethered nucleoside triphosphates
CY1116582T1 (el) Ανθρωπινα αντισωματα που δεσμευουν το γονιδιο-3 ενεργοποιησης λεμφοκυτταρων (leg-3), και χρησεις εξ' αυτων
CY1112781T1 (el) 2'-φθορο-2'-δεοξυτετραϋδροουριδινες ως αναστολεις αποαμινασης κυτιδινης
CY1109649T1 (el) Αντιγονα και συνθεσεις απο neisseria
CY1117963T1 (el) Αντισωματα που προσδενουν τα il-17a και il-17f
CY1110187T1 (el) Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ιι
MX2009008620A (es) Un metodo para mejorar la respuesta de celulas t.
LTPA2018502I1 (lt) Per burną vartojamos kladribino kompozicijos
DK1483294T3 (da) Internaliserende anti-CD74-antistoffer og fremgangsmåder til deres anvendelse
CY1118003T1 (el) Αναπτυξη συστατικων εμβολιου ιου δαγκειου
HK1135431A1 (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
BRPI0708344B8 (pt) vetores adenovirais quiméricos e composição imunogênica
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
HK1134098A1 (en) Antibodies binding to the tumour associated antigen tat10772 for the diagnosis and treatment of tumor
CN101687022A8 (zh) Prame衍生的肽以及包括该肽的免疫原组合物
MX2010003574A (es) Anticuerpos il-23.
EP1594536A4 (en) ADJUVANT INFLUENZA VACCINE
WO2006066003A3 (en) Methods and compositions for induction or promotion of immune tolerance